NON-SMALL CELL LUNG CANCER

This study tested a new way to deliver radiation for small lung tumors in just one visit, without the usual planning scan. Ten patients with early-stage lung cancer or limited lung metastases received a single, high-dose radiation treatment in about 2-3 hours, instead of the typi…

This study looked at people with a certain type of advanced lung cancer (KRAS G12C) who still had signs of cancer after standard treatment. Instead of staying on the usual drug durvalumab, some switched to a targeted pill called sotorasib. The goal was to see if switching could k…

This study tested a combination of two drugs, atezolizumab and bevacizumab, as the first treatment for people with advanced non-squamous non-small cell lung cancer that has a high number of genetic mutations. The goal was to see if this drug pair could help keep the cancer from g…

This study tested a personalized approach for 153 adults with advanced lung adenocarcinoma. Treatment was chosen based on specific gene mutations (EGFR and BRCA1) in each patient's tumor. The goal was to see if this tailored strategy could improve tumor shrinkage and overall surv…

This study tested a new drug called BA3011, given alone or with an immunotherapy drug, in 85 adults with advanced non-small cell lung cancer that had stopped responding to prior treatments. The goal was to see if the drug could shrink tumors and to check for side effects. The res…

This early-phase study tested a combination of two drugs, bexarotene and Iressa, in 6 people with advanced non-small cell lung cancer who had already tried other treatments. The goal was to see if the combination was safe and could help control the disease. The study looked at ho…

This early-stage study tested a custom-made yeast vaccine designed to train the immune system to recognize and attack leftover cancer cells. Five adults with various cancers (like colorectal, breast, or lung) who had completed initial treatment received the vaccine. The goal was …

This trial tested several targeted drugs in people with non-small cell lung cancer whose tumors had specific genetic changes. The goal was to see if these drugs could shrink tumors or delay cancer growth. Over 400 participants received treatment based on their tumor's genetic pro…

This study tested a drug called AZD9291 in 171 people from Asia Pacific with advanced non-small cell lung cancer that had stopped responding to earlier treatments. All participants had a specific gene mutation (T790M) in their tumors. The goal was to see if the drug could shrink …

This early-phase study tested a new drug called BAY 2862789 in 45 people with advanced solid tumors, including non-small cell lung cancer. The drug works by activating immune cells to fight cancer. The main goals were to check safety, find the best dose, and see how the drug move…

This study tested a new drug (ningetinib) combined with an existing targeted therapy (gefitinib) in 108 people with advanced lung cancer whose cancer had stopped responding to previous treatments. The goal was to find the safest dose and see if the combination could shrink tumors…

This study tested a combination of two drugs (NT-I7 and pembrolizumab) in 215 adults with advanced solid tumors that had returned or stopped responding to standard treatments. The goal was to find a safe dose and see if the combination could shrink tumors. The study also looked a…

This study tested whether adding a bronchoscopy-guided treatment to standard immunotherapy and chemotherapy could help people with advanced central non-small cell lung cancer. The trial involved 33 adults whose cancer could not be surgically removed. Researchers measured how long…

This early-phase study tested whether adding L-NMMA to the immunotherapy drug pembrolizumab is safe for people with several types of advanced cancer. The goal was to see if blocking a molecule that can hide cancer from the immune system could make treatment more effective. Only 1…

This phase 3 study tested adding the immunotherapy drug cemiplimab to standard chemotherapy for people with advanced non-small cell lung cancer. The goal was to see if the combination helps patients live longer and keeps the cancer from growing. About 789 participants received ei…

This early-phase trial tested a new drug called TPST-1495, given alone or with pembrolizumab, in 89 people with advanced solid tumors (like colorectal, lung, or head and neck cancers) that had stopped responding to standard treatments. The main goal was to find a safe dose and ch…

This study tested a combination of two drugs, RMC-4630 and sotorasib, in 47 adults with a specific type of advanced lung cancer (KRASG12C mutation) that had worsened after prior treatments. The goal was to see if the combination could shrink tumors. The study is now complete, and…

This trial tested a new drug called AK112 in 108 people with advanced non-small cell lung cancer. The drug targets both PD-1 and VEGF to attack cancer cells and cut off their blood supply. The study aimed to see if the drug shrinks tumors and how safe it is. Participants had stag…

This study tested a new drug (TJ004309) combined with an existing immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. The treatment i…

This study tested whether a combination of two targeted drugs (savolitinib and osimertinib) works better than standard chemotherapy for people with advanced non-small cell lung cancer that has a specific genetic change (MET amplification) and has stopped responding to first-line …

This study tested a daily pill called sotorasib in 42 people with advanced lung cancer that has a specific KRAS G12C mutation and who had not received prior treatment. The goal was to see if the drug could shrink tumors and control the disease. Researchers also monitored side eff…

This early-phase study tested whether a treatment made from a patient's own immune cells (tumor-infiltrating lymphocytes) is safe for people with advanced solid tumors like melanoma, cervical cancer, and lung cancer. 43 participants received the therapy to find the best dose and …

This study tested whether a shot under the skin (subcutaneous) of the immunotherapy drug atezolizumab works as well as the standard IV drip for people with advanced non-small cell lung cancer. About 438 patients who had already tried chemotherapy took part. The goal was to see if…

This early-stage study tested several combinations of cancer drugs in 60 people with advanced or metastatic cancer. The main goal was to find safe doses for future studies. The trial looked at different drug mixes, including niraparib, TSR-042, bevacizumab, and various chemothera…

This study tested three different drug combinations in 151 people with advanced non-small cell lung cancer that had not been treated before. The goal was to see if the combinations could shrink tumors or slow cancer growth. Participants received either one drug alone or two or th…

This phase 3 study tested whether adding plinabulin to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer. 559 adults who had already tried one or two prior treatments were randomly assigned to receive either the combination or che…

This study tested whether the immunotherapy drug pembrolizumab (Keytruda) could help prevent lung cancer from coming back in people with early-stage non-small cell lung cancer (stages IB to IIIA) who had already had surgery and standard chemotherapy. About 1,177 participants rece…

This study tested a mix of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy (paclitaxel) in 46 people with untreated metastatic non-small cell lung cancer. The goal was to see if the combination could slow cancer growth or improve survival. The approach aims t…

This study looked at side effects of the drug Lorbrena in 1290 people with non-small cell lung cancer after it was already on the market. The main focus was on nervous system problems and liver issues. The goal was to better understand what factors might increase these risks.

This early-stage study tested a new drug (BGB-A445) alone and with another drug (tislelizumab) in 204 people with advanced solid tumors like lung, head and neck, and nasopharyngeal cancers. The main goal was to check safety and find the best dose. This is not a cure, but aims to …

This early-phase study tested a personalized cancer vaccine (RO7198457) in 273 patients with advanced solid tumors like melanoma, lung, and breast cancer. The vaccine was given alone or with an immunotherapy drug (atezolizumab) to see if it was safe and how the body responded. Th…

This study tested whether adding an experimental drug (either a CCR2/5-inhibitor or an anti-IL-8) to the immunotherapy nivolumab before and after surgery could help shrink tumors and improve long-term survival in people with non-small cell lung cancer or liver cancer. 48 adults w…

This study tested whether adding erlotinib to docetaxel chemotherapy helps people with advanced non-small cell lung cancer live longer without their disease getting worse. 156 adults whose cancer returned after initial treatment took part. Results focused on progression-free surv…

This study tested a drug called durvalumab in 446 people with advanced non-small cell lung cancer whose disease had worsened after at least two prior treatments, including chemotherapy. The goal was to see if the drug could shrink tumors and how safe it was. Participants received…

This study looked at 76 people with advanced non-small cell lung cancer or head and neck squamous cell cancer who were already starting immunotherapy. Within two weeks of their first dose, they received a short course of radiation to one tumor site. The goal was to see if this co…

This study looked at whether giving a combination of immunotherapy and chemotherapy at a specific time of day helps people with advanced non-small cell lung cancer live longer without their disease getting worse. 210 adults who had not received prior treatment were randomly assig…

This study tested an experimental drug called DS-1062a in 137 adults with advanced or metastatic non-small cell lung cancer that had specific genetic changes. All participants had already tried targeted therapy and platinum-based chemotherapy without success. The main goal was to…

This study tested a new drug combination (tiragolumab plus atezolizumab) against a placebo plus atezolizumab in 135 people with advanced non-small cell lung cancer who had not received prior treatment. The goal was to see if the combo could shrink tumors or delay cancer growth. P…

This study tested a new drug called gimistotug (BGB-A445) combined with other investigational medicines in 35 people with advanced non-small cell lung cancer who had already received standard treatments like immunotherapy and chemotherapy. The main goal was to see if the combinat…

This study evaluated the safety of the drug sotorasib in 102 Chinese adults with advanced non-small cell lung cancer that has a specific genetic mutation (KRAS G12C). The main goal was to track side effects, including liver, lung, and kidney problems. Researchers also measured ho…

This study tested whether adding immunotherapy drugs (nivolumab alone or with ipilimumab) after standard chemoradiation helps people with stage III non-small cell lung cancer that cannot be removed by surgery. 105 participants were randomly assigned to one of two treatment groups…

This study tested whether adding the experimental drug custirsen to the standard chemotherapy docetaxel helps people with advanced non-small cell lung cancer live longer. The trial included 664 adults whose cancer had spread and who had already tried one prior treatment. Research…

This early-phase study tested whether adding the drug copanlisib to the standard immune therapy durvalumab is safe and can help overcome resistance in people with stage III non-small cell lung cancer that cannot be removed by surgery. Eleven participants who had already received …

This study tested whether adding immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy before surgery helps people with early-stage non-small cell lung cancer. About 500 participants received either immunotherapy plus chemo, immunotherapy alone, or chemo alone b…

This study tested an oral drug called PLB1001 in 145 people with advanced non-small cell lung cancer whose tumors have a specific genetic change (c-Met dysregulation). The main goal was to see how many patients' tumors shrank or disappeared. The drug is taken twice daily and aims…

This study tested whether adding lenvatinib to the immunotherapy drug pembrolizumab helps people with advanced non-small cell lung cancer (NSCLC) who have not had prior treatment. The trial included 623 adults whose tumors show at least 1% PD-L1. The goal was to see if the combin…

This early-stage study tested a new daily pill, JAB-3312, in 40 adults with advanced solid tumors (like lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. Researchers also looked…

This early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had minimal residual disease (small amounts of cancer left after standard treatment). The goal was to see if t…

This study tested a combination of two drugs, tucidinostat and tislelizumab, as a first treatment for people with a type of advanced lung cancer that has a specific marker (PD-L1 positive). The goal was to see if the combination could help control the cancer longer than standard …

This early-stage study tested a new drug called CTX-471, given alone or with another immunotherapy (pembrolizumab), in 100 adults with advanced cancers like lung cancer, melanoma, or head and neck cancer that had stopped responding to standard PD-1/PD-L1 inhibitors. The main goal…

This early-stage study tested a new drug called PF-07257876 in 29 people with advanced lung, head/neck, or ovarian cancers that had stopped responding to standard treatments. The drug is designed to help the immune system attack cancer cells. The main goals were to find a safe do…

This study tested giving the cancer drug nivolumab as a shot under the skin (instead of through an IV) to people with advanced cancers like lung, kidney, melanoma, liver, and colorectal cancer. The main goal was to see how the drug moves in the body and to check for side effects.…

This study tested whether combining two drugs, brentuximab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma, lung cancer, or head and neck cancer that has spread. About 161 adults took part. The main goal was to see how many patients had their tumors …

This study tested a new drug called lazertinib against an older drug, gefitinib, in 393 people with advanced non-small cell lung cancer that has specific EGFR mutations. Participants took one of the two pills daily as their first treatment. The main goal was to see how long the c…

This study tested a new drug called ensartinib in 131 people with advanced solid tumors, including a type of lung cancer driven by an ALK gene change. The main goals were to find the safest dose and see if it shrinks tumors. Results helped guide further research on this targeted …

This study tested a combination of two chemotherapy drugs (platinum and gemcitabine) plus an immunotherapy drug (sintilimab) in 20 people with advanced squamous non-small cell lung cancer. The goal was to see if this treatment could shrink tumors and help patients live longer wit…

This study tested whether adding a new drug called tiragolumab to the standard immunotherapy atezolizumab works better than atezolizumab alone for people with advanced non-small cell lung cancer that has not been treated before. About 620 participants with high levels of a protei…

This study looked at whether giving palliative radiation to several tumor sites before starting standard immunotherapy and chemotherapy can help people with metastatic non-small cell lung cancer. Fifty adults with cancer that had spread and low PD-L1 levels received radiation to …

This study looked at how well the drug Tabrecta works and how safe it is for people with a certain type of advanced lung cancer (non-small cell lung cancer with a MET exon 14 skipping mutation). It included 109 patients who were followed for up to one year. The main goals were to…

This early-phase study tested a new drug (GDC-1971) combined with standard treatments for people with advanced lung or colorectal cancer. The main goal was to check safety and find the right dose. Only 10 people took part, so results are very preliminary.

This early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nint…

This early-phase study tested the drug RAD001 (everolimus) together with radiation therapy in 26 people with advanced non-small cell lung cancer that could not be removed by surgery. The goal was to find the safest dose and see how well the combination worked. Participants took R…

This study tested a drug called serplulimab combined with chemotherapy for people with stage II-IIIA non-small cell lung cancer that could be removed by surgery. The treatment was given before and after surgery to see if it could shrink tumors and improve outcomes. 30 participant…

This study tested whether combining the immunotherapy drug nivolumab with another drug (ipilimumab) or with standard chemotherapy could help people with advanced non-small cell lung cancer live longer or keep their cancer from growing. About 2,700 patients who had not received pr…

This study tested a combination of two targeted drugs, encorafenib and binimetinib, in 98 people with advanced non-small cell lung cancer that has a specific BRAF gene mutation. The goal was to see if the drugs could shrink tumors and how safe they were. Participants had either n…

This early-phase study tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that targets a protein called IL-27 to help the immune system fight cancer. …

This study tested a combination of two drugs, nivolumab and ALT-803, in 67 people with advanced non-small cell lung cancer that had already been treated. The goal was to see if the combination is safe and how well it shrinks tumors. The approach aims to boost the immune system to…

This study tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with stage IV non-small cell lung cancer live longer. 719 adults who had not received prior treatment for their advanced cancer took part. The main goal was t…

This study tested whether using local ablative therapy (LAT) — treatments like radiation or surgery that target tumors directly — can control metastatic non-small cell lung cancer when a blood test shows rising cancer DNA (MRD). 37 patients with stage IV lung cancer who had stabl…

This early-phase study tested a new treatment for people with advanced non-small cell lung cancer that had grown or returned after standard therapy. Researchers took patients' own immune cells, genetically modified them in a lab to target cancer cells, and infused them back after…

This study tested a combination of two drugs, pembrolizumab (an immunotherapy) and Imprime PGG (a yeast-based immune booster), in 35 adults with advanced non-small cell lung cancer that had worsened after initial treatment. The goal was to see if the combo could shrink tumors or …

This study tested a personalized approach to radiation therapy for people with stage III lung cancer that cannot be removed by surgery. During standard chemo-radiation, doctors used PET scans to see which parts of the tumor were still active and gave those areas a higher radiatio…

This study tested a drug called trastuzumab deruxtecan in 152 people with a specific type of advanced lung cancer (HER2-mutated) that had gotten worse after standard treatment. The main goal was to see if the drug could shrink tumors. The approach uses a targeted therapy that del…

This study tested whether giving drugs based on the genetic makeup of a person's lung cancer could help control the disease. About 50 adults with advanced non-small cell lung cancer received either immunotherapy (atezolizumab) alone or with chemotherapy, or targeted drugs like ve…

This study tested whether adding the drug camrelizumab to standard chemotherapy and radiation helps control lung cancer that has spread to the brain. It involved 60 adults with a type of lung cancer called non-small cell lung cancer who had not received chemotherapy before. The g…

This study tested a new way of giving radiation therapy combined with immunotherapy for people with advanced non-small cell lung cancer that does not have certain genetic mutations. The goal was to see if mixing high-dose and low-dose radiation could help the immune system fight …

This early-phase study tested adding the drug pirfenidone to standard chemotherapy for people with advanced non-small cell lung cancer. The main goals were to find a safe dose and see if the combination could shrink tumors. 48 participants were enrolled, and the study is now comp…

This study tested whether adding the experimental drug OSI-906 to the standard targeted therapy erlotinib (Tarceva) helps people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. 88 participants who had not received prior chemotherapy were randomly …

This study tested a new pill called AZD3759 against standard targeted therapies (gefitinib or erlotinib) as a first treatment for people with advanced non-small cell lung cancer that has a specific gene mutation (EGFR) and has spread to the brain. The trial involved 492 adults. T…

This study tested a drug called tislelizumab, given alone or with other treatments before surgery, in 121 adults with stage II to IIIA non-small cell lung cancer that could be removed. The goal was to see if these treatments could shrink or eliminate the tumor before the operatio…

This study tested a new drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The trial was early-stage…

This study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…

This early-phase trial tested injecting the chemotherapy drug cisplatin directly into lung tumors during a bronchoscopy for people with early-stage non-small cell lung cancer. The goal was to find the safest dose and see how well the tumor responds. Only 6 participants were enrol…

This study tested two oral medications, alectinib and crizotinib, in 303 people with a specific type of advanced lung cancer (ALK-positive non-small cell lung cancer) who had not received prior treatment. Participants took one of the drugs twice daily until their disease worsened…

This early-stage study tested whether adding PB101 (a patient's own natural killer cells) to standard targeted therapy is safe for people with advanced EGFR-mutated non-small cell lung cancer. Eight adults with stage IIIB/IV disease received the combination. The main goal was to …

This study looked at whether adding a blood test (liquid biopsy) to the standard tissue test helps find more EGFR gene mutations in people with advanced non-small cell lung cancer. Over 500 patients who had not yet been treated were tested using both methods. The goal was to see …

This study looked at whether a blood test can find gene changes in people with advanced lung cancer. 22 adults gave a blood sample, and the results were compared to standard tissue tests. The goal was to see if the blood test is a reliable and practical option for guiding treatme…

This study tested a new method for PET scans that tracks breathing to get clearer images of lung tumors. 103 adults with small lung nodules took part. The goal was to see if this technique helps doctors find and measure lung cancer more accurately.

This study tested whether a personalized exercise program helps people with early-stage lung cancer or cancer that spread to the lungs recover better after surgery. 182 participants were randomly assigned to either the exercise program or usual care. The main goal was to see if t…

This study looked at whether people with non-small cell lung cancer prefer getting their medication as a shot under the skin (subcutaneous) or through a needle in a vein (intravenous). About 179 adults took part, including those with early-stage cancer after surgery and those wit…

This study tested a faster radiation treatment called Quad Shot for people with advanced non-small cell lung cancer who are also receiving chemotherapy or immunotherapy. The goal was to see if giving radiation in fewer, higher doses is safe and less likely to interfere with their…

This study tested whether using a non-invasive breathing mask (like a CPAP machine) for at least 7 days before lung cancer surgery could reduce serious heart and lung complications. The trial included 300 adults with lung cancer who also had breathing problems, obesity, or heart …

This study tested two different radiotherapy schedules for people with advanced non-small cell lung cancer. One group received the standard 6-week treatment, while the other received a shorter 4-week course based on PET scans. The main goal was to see which schedule caused fewer …

This study tested whether a nutritional supplement with essential amino acids could help lung cancer patients who are losing weight build more protein in their bodies. 41 patients with advanced non-small cell lung cancer took part. The goal was to see if this supplement could red…

This study tested an experimental drug called ponsegromab in 187 people with lung, pancreatic, or colorectal cancer who were experiencing severe weight loss and fatigue (cachexia) and had high levels of a protein called GDF-15. The goal was to see if the drug could help patients …

This study looked at whether a home-based exercise program can help people with non-small cell lung cancer manage severe tiredness (fatigue) after surgery. 235 adults took part. The program was designed to be simple, safe, and low-cost. The goal was to see if it could reduce fati…

This study tested a new bendable surgical tool (SurgeoFlex Grasp) against a standard rigid tool in 100 adults with early-stage lung cancer undergoing keyhole surgery. The goal was to see if the flexible tool makes lymph node removal faster, reduces instrument clashes, and eases s…

This study tested whether involving family in palliative care helps people with advanced lung cancer feel better. 110 patients were split into two groups: one received standard care, the other added family support, education, and counseling for 8 weeks. The goal was to see if thi…

This study reviewed medical records from 240 adults in Poland with advanced non-small cell lung cancer who received a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy as their first treatment. The goal was to see how well the treatment worked in…

This study looked at whether a special type of scan called 4D PET-CT can help doctors plan radiation therapy better for people with non-small cell lung cancer. Seven patients had both a standard CT scan and a 4D PET-CT scan, and researchers compared the radiation target areas fro…

This study looked at blood samples from 50 people with a specific type of lung cancer (ALK-positive) whose cancer had stopped responding to targeted treatments. The goal was to find genetic changes in the blood that explain why the drugs stop working. By matching these changes to…

This study looked at the nutrition and body composition of 25 adults with non-small-cell lung cancer who were taking the drug osimertinib. Researchers measured weight, muscle mass, and strength to see how common malnutrition and muscle loss were, and how these affected quality of…

This study looked at using simple blood tests (liquid biopsies) to find a specific genetic change called T790M that makes lung cancer stop responding to certain targeted therapies. Researchers followed 70 patients with advanced non-small cell lung cancer in Tunisia to see how oft…

This study followed 196 people with advanced lung or stomach cancer who had not yet received treatment. Researchers wanted to see if emotional distress before starting immunotherapy, along with certain blood markers of inflammation and metabolism, could predict how long patients …

This study looked at whether information from real cancer patients' medical records can produce the same results as a previous clinical trial (FLAURA) for a lung cancer drug. Researchers analyzed data from nearly 5,000 people with non-small cell lung cancer to see if real-world d…

This study looked at 62 people with ALK-positive lung cancer whose tumors had stopped responding to newer targeted drugs. Instead of a tissue biopsy, researchers used a blood test (liquid biopsy) to find genetic changes that cause resistance. The goal was to better understand the…

This study looked at whether people with advanced cancers (melanoma, kidney, or lung cancer) receiving their first immunotherapy treatment could successfully collect small blood samples at home using a finger-prick method. The goal was to see if this approach is practical and rel…

This study looked at pieces of a protein called Met in lung cancer tissue from 56 patients. Researchers used special lab tests to see which pieces were present and whether they were active. The goal was to learn more about the disease, not to test a new treatment.

This study looked at 40 people with advanced non-small cell lung cancer whose tumors have high PD-L1 levels. They received pembrolizumab (Keytruda) as their first treatment. Researchers used PET scans after just one dose to see if early changes in tumor sugar uptake could predict…

This study looked at whether a test using 6 different markers from tumor samples could predict how well patients with advanced non-small cell lung cancer would respond to a combination of immunotherapy (pembrolizumab) and chemotherapy. 106 adults participated. The goal was to see…

This study tested a new blood test (liquid biopsy) to find cancer markers in 135 people with head and neck, lung, or skin cancer. The goal was to see if the blood test works as well as a standard tissue biopsy. The study did not provide treatment but aimed to improve how doctors …

This study looked at 212 adults with advanced non-small cell lung cancer who received the drug nivolumab after chemotherapy. Researchers tracked how many patients were still alive 12, 24, and 36 months after starting treatment. The goal was to see how well the drug works in every…

This study aimed to find immune-related biomarkers that could predict how well patients with non-small cell lung cancer respond to the drug atezolizumab. Researchers analyzed blood and tumor samples from 100 participants to track immune cell changes and genetic markers. The goal …

This study reviewed medical records of 350 Australian patients with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). Researchers looked at how long patients stayed on the drug osimertinib when it was given as their first or second treatment, and h…

This study created a detailed database of 518 adults with non-small cell lung cancer who had a genetic mutation. Researchers collected information on patients' age, smoking history, and cancer stage to see how these factors relate to different mutations. The goal was to better un…

This study looked at medical records of 833 people with advanced non-small cell lung cancer to understand what treatments they received and how long they lived. Researchers collected data from doctors' surveys across multiple countries. The goal was to learn about real-world care…

This study looked at whether a special type of PET scan (parametric imaging) can better predict if non-small cell lung cancer will come back within a year after treatment. Researchers compared this new scan method to the standard PET scan in 40 patients who had chemotherapy and r…

This study looked at how the lung cancer drug AZD9291 (osimertinib) affects the breakdown of simvastatin, a common cholesterol medicine, in 52 adults with a specific type of advanced lung cancer (EGFR mutation-positive NSCLC) that had stopped responding to earlier treatments. The…

This study looked at how a new cancer drug, MK-1084, changes the way two other medicines (midazolam and digoxin) are processed in the body. Twenty-eight healthy adults took part to help researchers understand if MK-1084 affects drug levels. The results will guide safe dosing when…

This study looked back at the medical records of 60 people with advanced lung cancer to see if taking a common heart medication (beta-blockers) alongside immunotherapy affected their treatment results. Researchers compared how long the cancer was controlled and survival rates bet…